Amgen Inc. (NASDAQ: AMGN) announced that its Phase 3 VESALIUS-CV clinical trial met dual primary endpoints, demonstrating that Repatha (evolocumab) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE